GNPAT
Basic information
Region (hg38): 1:231241207-231277973
Links
Phenotypes
GenCC
Source:
- rhizomelic chondrodysplasia punctata type 2 (Definitive), mode of inheritance: AR
- rhizomelic chondrodysplasia punctata type 2 (Strong), mode of inheritance: AR
- glyceronephosphate O-acyltransferase deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Rhizomelic chondrodysplasia punctata, type 2 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic | 1405476; 8466247; 7530787; 7541833; 9536089; 20583171; 21990100 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (19 variants)
- Rhizomelic chondrodysplasia punctata type 2 (7 variants)
- Rhizomelic chondrodysplasia punctata (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GNPAT gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 121 | 129 | ||||
missense | 100 | 108 | ||||
nonsense | 12 | 16 | ||||
start loss | 0 | |||||
frameshift | 14 | 14 | 28 | |||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 10 | |||||
splice region | 1 | 1 | 6 | 26 | 1 | 35 |
non coding | 15 | 114 | 21 | 150 | ||
Total | 20 | 36 | 121 | 239 | 26 |
Highest pathogenic variant AF is 0.00000658
Variants in GNPAT
This is a list of pathogenic ClinVar variants found in the GNPAT region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-231241226-A-C | Rhizomelic chondrodysplasia punctata type 2 | Uncertain significance (Jan 13, 2018) | ||
1-231241232-G-C | Rhizomelic chondrodysplasia punctata type 2 | Uncertain significance (Jan 13, 2018) | ||
1-231241234-G-A | Rhizomelic chondrodysplasia punctata type 2 | Benign/Likely benign (Oct 21, 2018) | ||
1-231241258-C-T | Rhizomelic chondrodysplasia punctata type 2 | Uncertain significance (Jan 13, 2018) | ||
1-231241295-C-T | Rhizomelic chondrodysplasia punctata type 2 | Benign/Likely benign (Jun 14, 2018) | ||
1-231241297-G-T | Rhizomelic chondrodysplasia punctata type 2 | Uncertain significance (Jan 13, 2018) | ||
1-231241325-A-G | Rhizomelic chondrodysplasia punctata type 2 | Uncertain significance (Jan 12, 2018) | ||
1-231241332-C-A | Rhizomelic chondrodysplasia punctata type 2 | Uncertain significance (Jan 13, 2018) | ||
1-231241332-C-T | not provided (-) | |||
1-231241335-C-T | Rhizomelic chondrodysplasia punctata type 2 • not specified | Benign (Aug 10, 2021) | ||
1-231241373-C-T | Rhizomelic chondrodysplasia punctata type 2 | Uncertain significance (Jan 12, 2018) | ||
1-231241401-A-G | Uncertain significance (Aug 07, 2021) | |||
1-231241401-ACT-A | Rhizomelic chondrodysplasia punctata type 2 | Likely pathogenic (Jul 03, 2023) | ||
1-231241404-C-T | not specified • Rhizomelic chondrodysplasia punctata type 2 | Benign (Jan 31, 2024) | ||
1-231241408-T-C | Likely benign (Dec 02, 2022) | |||
1-231241415-G-T | Uncertain significance (Nov 03, 2021) | |||
1-231241420-C-G | Likely benign (Aug 28, 2023) | |||
1-231241424-ACCAGTC-A | Uncertain significance (Jan 02, 2021) | |||
1-231241434-G-C | Uncertain significance (Aug 14, 2021) | |||
1-231241435-C-T | Rhizomelic chondrodysplasia punctata type 2 | Conflicting classifications of pathogenicity (Jan 22, 2024) | ||
1-231241441-C-T | Likely benign (Apr 28, 2023) | |||
1-231241443-T-C | Rhizomelic chondrodysplasia punctata type 2 | Conflicting classifications of pathogenicity (Jan 19, 2024) | ||
1-231241444-G-A | Likely benign (Sep 21, 2023) | |||
1-231241444-G-T | Likely benign (Dec 15, 2022) | |||
1-231241447-C-T | Likely benign (Sep 22, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GNPAT | protein_coding | protein_coding | ENST00000366647 | 16 | 36767 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.304 | 0.696 | 125727 | 0 | 21 | 125748 | 0.0000835 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.674 | 316 | 352 | 0.899 | 0.0000187 | 4484 |
Missense in Polyphen | 89 | 111.73 | 0.79656 | 1425 | ||
Synonymous | -0.0637 | 125 | 124 | 1.01 | 0.00000634 | 1282 |
Loss of Function | 4.19 | 8 | 34.6 | 0.231 | 0.00000181 | 434 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000181 | 0.000181 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000465 | 0.0000462 |
European (Non-Finnish) | 0.0000968 | 0.0000967 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Disease
- DISEASE: Rhizomelic chondrodysplasia punctata 2 (RCDP2) [MIM:222765]: A form of rhizomelic chondrodysplasia punctata, a disease characterized by severely disturbed endochondral bone formation, rhizomelic shortening of femur and humerus, vertebral disorders, dwarfism, cataract, cutaneous lesions, facial dysmorphism, and severe mental retardation with spasticity. {ECO:0000269|PubMed:11152660, ECO:0000269|PubMed:21990100, ECO:0000269|PubMed:9536089}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Glycerophospholipid metabolism - Homo sapiens (human);Peroxisome - Homo sapiens (human);Plasmalogen Synthesis;Triacylglyceride Synthesis;Metabolism of lipids;Metabolism of proteins;Metabolism;Peroxisomal protein import;Glycerophospholipid metabolism;Glycerophospholipid biosynthesis;Phospholipid metabolism;Plasmalogen biosynthesis;Synthesis of PA
(Consensus)
Recessive Scores
- pRec
- 0.265
Intolerance Scores
- loftool
- 0.328
- rvis_EVS
- -0.2
- rvis_percentile_EVS
- 39.11
Haploinsufficiency Scores
- pHI
- 0.521
- hipred
- N
- hipred_score
- 0.426
- ghis
- 0.553
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.977
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gnpat
- Phenotype
- endocrine/exocrine gland phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; pigmentation phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- protein targeting to peroxisome;fatty acid metabolic process;phosphatidic acid biosynthetic process;synapse assembly;response to nutrient;ether lipid biosynthetic process;phospholipid biosynthetic process;cerebellum morphogenesis;paranodal junction assembly;response to drug;response to starvation;membrane organization;response to fatty acid
- Cellular component
- peroxisome;peroxisomal membrane;peroxisomal matrix;cytosol;membrane;mitochondrial membrane
- Molecular function
- signaling receptor binding;glycerone-phosphate O-acyltransferase activity;palmitoyl-CoA hydrolase activity